Literature DB >> 22658928

Immune markers and correlates of protection for vaccine induced immune responses.

Aneesh Thakur1, Lasse E Pedersen, Gregers Jungersen.   

Abstract

Vaccines have been a major innovation in the history of mankind and still have the potential to address the challenges posed by chronic intracellular infections including tuberculosis, HIV and malaria which are leading causes of high morbidity and mortality across the world. Markers of an appropriate humoral response currently remain the best validated correlates of protective immunity after vaccination. Despite advancements in the field of immunology over the past few decades currently there are, however, no sufficiently validated immune correlates of vaccine induced protection against chronic infections in neither human nor veterinary medicine. Technological and conceptual advancements within cell-mediated immunology have led to a number of new immunological read-outs with the potential to emerge as correlates of vaccine induced protection. For T(H)1 type responses, antigen-specific production of interferon-gamma (IFN-γ) has been promoted as a quantitative marker of protective cell-mediated immune responses over the past couple of decades. More recently, however, evidence from several infections has pointed towards the quality of the immune response, measured through increased levels of antigen-specific polyfunctional T cells capable of producing a triad of relevant cytokines, as a better correlate of sustained protective immunity against this type of infections. Also the possibilities to measure antigen-specific cytotoxic T cells (CTL) during infection or in response to vaccination, through recombinant major histocompatibility complex (MHC) class I tetramers loaded with relevant peptides, has opened a new vista to include CTL responses in the evaluation of protective immune responses. Here, we review different immune markers and new candidates for correlates of a protective vaccine induced immune response against chronic infections and how successful they have been in defining the protective immunity in human and veterinary medicine.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658928     DOI: 10.1016/j.vaccine.2012.05.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  61 in total

1.  Commonly administered bacille Calmette-Guerin strains induce comparable immune response.

Authors:  Jun-Fang Wang; Fu-Ying Dai; Xue-Li Gong; Lang Bao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

3.  Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis.

Authors:  Weifeng Zhang; Lianyan Wang; Yuan Liu; Xiaoming Chen; Jiahui Li; Tingyuan Yang; Wenqi An; Xiaowei Ma; Ruowen Pan; Guanghui Ma
Journal:  Pharm Res       Date:  2013-10-30       Impact factor: 4.200

4.  Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.

Authors:  Rezwanul Wahid; Stephanie Fresnay; Myron M Levine; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2016-09-12       Impact factor: 3.969

5.  Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy.

Authors:  Weifeng Zhang; Lianyan Wang; Tingyuan Yang; Yuan Liu; Xiaoming Chen; Qi Liu; Jilei Jia; Guanghui Ma
Journal:  Pharm Res       Date:  2015-05-28       Impact factor: 4.200

6.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

Review 7.  Animal Models for Tuberculosis in Translational and Precision Medicine.

Authors:  Lingjun Zhan; Jun Tang; Mengmeng Sun; Chuan Qin
Journal:  Front Microbiol       Date:  2017-05-04       Impact factor: 5.640

Review 8.  Progress in HIV vaccine development.

Authors:  Denise C Hsu; Robert J O'Connell
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

9.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

10.  Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.

Authors:  Laura Sticchi; Bianca Bruzzone; Patrizia Caligiuri; Emanuela Rappazzo; Michele Lo Casto; Laura De Hoffer; Giulia Gustinetti; Claudio Viscoli; Antonio Di Biagio
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.